Navidea Biopharmaceuticals Announces 2014 Annual Meeting Results
July 17 2014 - 3:44PM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a
biopharmaceutical company focused on precision diagnostic
radiopharmaceuticals, today announced the results of voting at its
2014 Annual Meeting of Stockholders (the Annual Meeting) held July
17, 2014. Approximately 79 percent of outstanding shares were
represented at the meeting.
At the Annual Meeting, Navidea’s stockholders:
- Elected Michael M. Goldberg M.D. to the
Navidea Board of Directors to serve for a term of three years;
- Voted in support of the Board-sponsored
proposal to approve the Company’s 2014 Stock Incentive Plan;
- Approved, on an advisory basis, the
compensation of the Company’s named executive officers; and,
- Ratified the appointment of BDO USA,
LLP to act as the Company’s independent registered public
accounting firm for 2014.
The final results are subject to verification by the independent
election inspectors and will be reported in a Form 8-K to be filed
by Navidea with the Securities and Exchange Commission in the next
few days.
Following the formal business portion of the Annual Meeting, Dr.
Michael Goldberg, Navidea Interim CEO, and other members of the
Navidea executive team made a series of presentations to
stockholders in attendance at the Annual Meeting, including
overviews on the following:
- Lymphoseek® (technetium Tc-99m
tilmanocept) Injection U.S. commercialization, label expansion and
global partnering activities;
- Manocept™ CD206 targeting platform
update, including a discussion of the new R-NAV venture; and,
- Neurodegenerative pipeline development
status.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics and radiopharmaceutical
agents. Navidea is developing multiple precision diagnostic
products and platforms, including Manocept™, NAV4694, NAV5001, and
NAV1800 (RIGScan™), to help identify the sites and pathways of
undetected disease and enable better diagnostic accuracy, clinical
decision-making and, ultimately, patient care. Lymphoseek®
(technetium Tc-99m tilmanocept) Injection, Navidea’s first
commercial product from the Manocept platform, was approved by the
FDA in March 2013. For more information, please visit
www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
Navidea BiopharmaceuticalsBrent Larson, 614-822-2330Executive VP
& CFOorSharon Correia, 978-655-2686Associate Director,
Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024